Gapping up
In reaction to strong earnings/guidance: LPSN +16.7%, WSTL +15.8%, FORM +10.9%, SKX +10.6%, HOLX +9.1%, VNDA +8.7%, OTEX +8.5%, PEGA +7.3%, NTRI +7.2%, ANIK +6.7%, TER +6.7%, RKUS +6.6%, NOK +6.5%, WDC +6.3%, ALU +5.9%, EPE +5.6%, HDSN +5.5%, APD +5.1%, CWST +4.9%, NE +4.7%, PPC +4.4%, NXPI +4.3%, RDS.A +4.1%, EROC+3.9%, SSNC +3.8%, KGC +3.4%, ATNI +3.1%, DEPO +2.8%, (also DepoMed announces Board rejection of the revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma), VRTX +2.3%, ARR +2.2%, SWK +2.2%, WYNN +2.1%, PODD +1.9%, SCTY +1.7%, SC +1.6%, ORLY +1.4%, CI +1.4%, INUV +1.3%, SU +1.2%, WMGI +1%, EURN +1%,NICE +1%, EHTH +0.9%, POT +0.9%
Select oil/gas related names showing strength: TOT +1.7%, BP +1.6%, STO +1.3%
Other news: UNIS +28.9% (announced the introduction of the Imperium platform of instant patch pumps for insulin; announced $45 mln equity purchase agreement with Lincoln Park Capital and $25 mln at-the-market facility with Cantor Fitzgerald), SGYP +21.2% (announces positive top-line results from its pivotal phase 3 clinical trial, evaluating the efficacy and safety of two different plecanatide treatment doses), ASND +16.3% (announces positive top-line results from its Phase 2 pediatric study of its TransCon Growth Hormone), IMNP +5.5% ( announces securing up to $21.5 million through two financing agreements), PPC +4.4% (announced Board approval for a new $150 million share repurchase program; co also reported earnings), BDBD +4.2% (Engaged Capital discloses 9.6% active stake in 13D filing; has engaged with management), LDOS +3.1% (late move higher on potential Pentagon contract win), EXPR +3% (to replace Associated Estates Realty (AEC) in the S&P SmallCap 600), X +3% (cont strength), DEPO +2% (announced Board rejection of the revised, unsolicited and non-binding proposal from Horizon Pharma; co also reported earnings), JBL +1.5% ( announces Board authorization for up to $100 million in share repurchases), GLPG +1.4% (co's selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study), BIDU +1.2% (announces $1 bln share repurchase program over the next 12 months), CS +1.1% (in symp with DB results)
Analyst comments: AKS +5.2% (upgraded to Overweight from Neutral at JP Morgan), ANGI +3.2% (upgraded to Market Perform from Under Perform at Northland Capital), LUV +1.4% (upgraded to Overweight from Neutral at JP Morgan), ORCL +0.8% (upgraded to Buy from Hold at Jefferies)
In reaction to strong earnings/guidance: LPSN +16.7%, WSTL +15.8%, FORM +10.9%, SKX +10.6%, HOLX +9.1%, VNDA +8.7%, OTEX +8.5%, PEGA +7.3%, NTRI +7.2%, ANIK +6.7%, TER +6.7%, RKUS +6.6%, NOK +6.5%, WDC +6.3%, ALU +5.9%, EPE +5.6%, HDSN +5.5%, APD +5.1%, CWST +4.9%, NE +4.7%, PPC +4.4%, NXPI +4.3%, RDS.A +4.1%, EROC+3.9%, SSNC +3.8%, KGC +3.4%, ATNI +3.1%, DEPO +2.8%, (also DepoMed announces Board rejection of the revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma), VRTX +2.3%, ARR +2.2%, SWK +2.2%, WYNN +2.1%, PODD +1.9%, SCTY +1.7%, SC +1.6%, ORLY +1.4%, CI +1.4%, INUV +1.3%, SU +1.2%, WMGI +1%, EURN +1%,NICE +1%, EHTH +0.9%, POT +0.9%
Select oil/gas related names showing strength: TOT +1.7%, BP +1.6%, STO +1.3%
Other news: UNIS +28.9% (announced the introduction of the Imperium platform of instant patch pumps for insulin; announced $45 mln equity purchase agreement with Lincoln Park Capital and $25 mln at-the-market facility with Cantor Fitzgerald), SGYP +21.2% (announces positive top-line results from its pivotal phase 3 clinical trial, evaluating the efficacy and safety of two different plecanatide treatment doses), ASND +16.3% (announces positive top-line results from its Phase 2 pediatric study of its TransCon Growth Hormone), IMNP +5.5% ( announces securing up to $21.5 million through two financing agreements), PPC +4.4% (announced Board approval for a new $150 million share repurchase program; co also reported earnings), BDBD +4.2% (Engaged Capital discloses 9.6% active stake in 13D filing; has engaged with management), LDOS +3.1% (late move higher on potential Pentagon contract win), EXPR +3% (to replace Associated Estates Realty (AEC) in the S&P SmallCap 600), X +3% (cont strength), DEPO +2% (announced Board rejection of the revised, unsolicited and non-binding proposal from Horizon Pharma; co also reported earnings), JBL +1.5% ( announces Board authorization for up to $100 million in share repurchases), GLPG +1.4% (co's selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study), BIDU +1.2% (announces $1 bln share repurchase program over the next 12 months), CS +1.1% (in symp with DB results)
Analyst comments: AKS +5.2% (upgraded to Overweight from Neutral at JP Morgan), ANGI +3.2% (upgraded to Market Perform from Under Perform at Northland Capital), LUV +1.4% (upgraded to Overweight from Neutral at JP Morgan), ORCL +0.8% (upgraded to Buy from Hold at Jefferies)